Global Cobamamide API Market Growth 2025-2031

Publication ID:

LPI08251646

Publication Date:

August 4, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cobamamide API market size is predicted to grow from US$ 4.4 million in 2025 to US$ 5.9 million in 2031; it is expected to grow at a CAGR of 5.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Cobamamide, also known as adenosylcobalamin or dibencozide, is a coenzyme form of vitamin B12. It's a naturally occurring, biologically active form of vitamin B12, crucial for various bodily functions. Cobamamide acts as a coenzyme in several metabolic pathways, including the metabolism of amino acids and fatty acids.
Cobamamide API, an active coenzyme form of vitamin B12, is crucial in treating megaloblastic anemia, neurological disorders, and regulating hematopoietic function due to its unique role in cellular metabolism. It also serves as a key ingredient in nutritional supplements and specialized medical formulations.
The market is characterized by technological innovation and diverse demand. Manufacturers focus on refining production processes and adopting green practices to enhance product stability, while R&D efforts concentrate on developing varied dosage forms like injectables and oral solutions. Growth is driven by the rising prevalence of chronic diseases among aging populations and the expanding nutritional supplement market. However, challenges include strict regulatory requirements, volatile raw material supplies, and intense competition.
The 鈥淐obamamide API Industry Forecast鈥� looks at past sales and reviews total world Cobamamide API sales in 2024, providing a comprehensive analysis by region and market sector of projected Cobamamide API sales for 2025 through 2031. With Cobamamide API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cobamamide API industry.
This Insight Report provides a comprehensive analysis of the global Cobamamide API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cobamamide API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cobamamide API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cobamamide API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cobamamide API.
This report presents a comprehensive overview, market shares, and growth opportunities of Cobamamide API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
笔耻谤颈迟测鈮�98%
Purity<98%
Segmentation by Application:
Oral Formulation
Injectable Formulation
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
China Pharmaceutical Holding Group
Ningxia Kingvit Pharmaceutical
Hebei Yuxing Bio-Engineering
HTBA
Interquim
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cobamamide API market?
What factors are driving Cobamamide API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cobamamide API market opportunities vary by end market size?
How does Cobamamide API break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cobamamide API Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cobamamide API by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cobamamide API by Country/Region, 2020, 2024 & 2031
2.2 Cobamamide API Segment by Type
2.2.1 笔耻谤颈迟测鈮�98%
2.2.2 Purity<98%
2.3 Cobamamide API Sales by Type
2.3.1 Global Cobamamide API Sales Market Share by Type (2020-2025)
2.3.2 Global Cobamamide API Revenue and Market Share by Type (2020-2025)
2.3.3 Global Cobamamide API Sale Price by Type (2020-2025)
2.4 Cobamamide API Segment by Application
2.4.1 Oral Formulation
2.4.2 Injectable Formulation
2.5 Cobamamide API Sales by Application
2.5.1 Global Cobamamide API Sale Market Share by Application (2020-2025)
2.5.2 Global Cobamamide API Revenue and Market Share by Application (2020-2025)
2.5.3 Global Cobamamide API Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Cobamamide API Breakdown Data by Company
3.1.1 Global Cobamamide API Annual Sales by Company (2020-2025)
3.1.2 Global Cobamamide API Sales Market Share by Company (2020-2025)
3.2 Global Cobamamide API Annual Revenue by Company (2020-2025)
3.2.1 Global Cobamamide API Revenue by Company (2020-2025)
3.2.2 Global Cobamamide API Revenue Market Share by Company (2020-2025)
3.3 Global Cobamamide API Sale Price by Company
3.4 Key Manufacturers Cobamamide API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cobamamide API Product Location Distribution
3.4.2 Players Cobamamide API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Cobamamide API by Geographic Region
4.1 World Historic Cobamamide API Market Size by Geographic Region (2020-2025)
4.1.1 Global Cobamamide API Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cobamamide API Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cobamamide API Market Size by Country/Region (2020-2025)
4.2.1 Global Cobamamide API Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cobamamide API Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cobamamide API Sales Growth
4.4 APAC Cobamamide API Sales Growth
4.5 Europe Cobamamide API Sales Growth
4.6 Middle East & Africa Cobamamide API Sales Growth
5 Americas
5.1 Americas Cobamamide API Sales by Country
5.1.1 Americas Cobamamide API Sales by Country (2020-2025)
5.1.2 Americas Cobamamide API Revenue by Country (2020-2025)
5.2 Americas Cobamamide API Sales by Type (2020-2025)
5.3 Americas Cobamamide API Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cobamamide API Sales by Region
6.1.1 APAC Cobamamide API Sales by Region (2020-2025)
6.1.2 APAC Cobamamide API Revenue by Region (2020-2025)
6.2 APAC Cobamamide API Sales by Type (2020-2025)
6.3 APAC Cobamamide API Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cobamamide API by Country
7.1.1 Europe Cobamamide API Sales by Country (2020-2025)
7.1.2 Europe Cobamamide API Revenue by Country (2020-2025)
7.2 Europe Cobamamide API Sales by Type (2020-2025)
7.3 Europe Cobamamide API Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cobamamide API by Country
8.1.1 Middle East & Africa Cobamamide API Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cobamamide API Revenue by Country (2020-2025)
8.2 Middle East & Africa Cobamamide API Sales by Type (2020-2025)
8.3 Middle East & Africa Cobamamide API Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cobamamide API
10.3 Manufacturing Process Analysis of Cobamamide API
10.4 Industry Chain Structure of Cobamamide API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cobamamide API Distributors
11.3 Cobamamide API Customer
12 World Forecast Review for Cobamamide API by Geographic Region
12.1 Global Cobamamide API Market Size Forecast by Region
12.1.1 Global Cobamamide API Forecast by Region (2026-2031)
12.1.2 Global Cobamamide API Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cobamamide API Forecast by Type (2026-2031)
12.7 Global Cobamamide API Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 China Pharmaceutical Holding Group
13.1.1 China Pharmaceutical Holding Group Company Information
13.1.2 China Pharmaceutical Holding Group Cobamamide API Product Portfolios and Specifications
13.1.3 China Pharmaceutical Holding Group Cobamamide API Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 China Pharmaceutical Holding Group Main Business Overview
13.1.5 China Pharmaceutical Holding Group Latest Developments
13.2 Ningxia Kingvit Pharmaceutical
13.2.1 Ningxia Kingvit Pharmaceutical Company Information
13.2.2 Ningxia Kingvit Pharmaceutical Cobamamide API Product Portfolios and Specifications
13.2.3 Ningxia Kingvit Pharmaceutical Cobamamide API Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Ningxia Kingvit Pharmaceutical Main Business Overview
13.2.5 Ningxia Kingvit Pharmaceutical Latest Developments
13.3 Hebei Yuxing Bio-Engineering
13.3.1 Hebei Yuxing Bio-Engineering Company Information
13.3.2 Hebei Yuxing Bio-Engineering Cobamamide API Product Portfolios and Specifications
13.3.3 Hebei Yuxing Bio-Engineering Cobamamide API Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Hebei Yuxing Bio-Engineering Main Business Overview
13.3.5 Hebei Yuxing Bio-Engineering Latest Developments
13.4 HTBA
13.4.1 HTBA Company Information
13.4.2 HTBA Cobamamide API Product Portfolios and Specifications
13.4.3 HTBA Cobamamide API Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 HTBA Main Business Overview
13.4.5 HTBA Latest Developments
13.5 Interquim
13.5.1 Interquim Company Information
13.5.2 Interquim Cobamamide API Product Portfolios and Specifications
13.5.3 Interquim Cobamamide API Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Interquim Main Business Overview
13.5.5 Interquim Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂